Navigation Links
Rx for Africa, Inc. Now Trading Under New Symbol (RXAF.PK)
Date:10/31/2007

NEW YORK, Oct. 31 /PRNewswire-FirstCall/ -- Rx for Africa, Inc. (Other OTC: RXAF.PK), announced today that effective immediately, its stock will now trade under the symbol RXAF.PK and that the name "Diamond Entertainment" and its symbol (DMON.PK) will no longer be used as part of the company's operations.

Rx for Africa, Inc. is the surviving company in a reverse merger completed in May 2007 with Diamond Entertainment Corp. - (DMON.PK). Through its wholly owned subsidiary, Rx Africa (Ethiopia) PLC (formerly known as Sunshine Pharmaceutical), Rx for Africa, Inc. owns and operates a state-of-the art pharmaceutical plant built on twenty three thousand square meters of land located south of Addis Ababa, Ethiopia. The Company is currently producing and marketing eight generic products in Ethiopia, with the goal of increasing production within the next 12 to 18 months to 50 products meeting US Food and Drug Administration (US FDA) and World Health Organization (WHO) good manufacturing practices (GMP). The expected product list includes three malaria drugs, three drugs for tuberculosis, nine HIV drugs, 27 antibiotics, and several each of anti-protozoans, anti-fungals and anti-emetics.

"The change in our name and symbol to Rx Africa, Inc. (RXAF.PK) better reflects our mission and focus as a world-class provider of generic medicines, including those for HIV/AIDS, malaria, tuberculosis and other diseases," commented Dr. Mulugetta Bezzabeh, CEO of Rx Africa (Ethiopia) PLC and board member of Rx for Africa, Inc. "Though presently focused solely in Ethiopia, we plan to expand our distribution throughout sub-Saharan Africa and beyond, and our new name and symbol are properly reflective of our path and vision. We are going to be a major player in the African pharmaceutical business."

For further information contact:

Howard Becker, Director

Rx for Africa, Inc.

(917) 553-1205

Forward Looking Statements

This press release contains
'/>"/>

SOURCE Rx for Africa, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2

Related medicine technology :

1. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
2. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
3. Neurocrine Biosciences Announces New Research Studies Presented at APSS Reveal Significant Under-Diagnosis of Insomnia
4. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
5. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
6. Cequent Pharmaceuticals Founder to Present tkRNAi Technology at the American Association of Cancer Research Annual Meeting in Los Angeles
7. Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention
8. MGI Pharma Announces Positive Results from a Pivotal Phase 3 Study of Aquavan Injection in Patients Undergoing Bronchoscopy
9. Use of Sequenoms MassARRAY System Leads to Significant Scientific Advances in Understanding Cancer, Diabetes and Drug-Resistant Malaria
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Newswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ...scovering,developingandcommercializingnoveldrugsto...efiscalyearendedSeptember30,2009.AtSeptember30,200...ndshortterminvestments. ,, PipelineUpdateand20... ,, InlateNovember2009,anindependentDataMonito...
(Date:11/25/2009)...ire/--BioTrendsResearchGroup,Inc.releasedWave1ofit...amulti-phasesyndicatedmarketresearchprojecttrackin...ductlaunchthroughthefirstsixmonthsofavailability.E...rom75uniqueDermatologistsandqualitativeinformation...ra,obstaclestouse,typicalpatienttypes,productperce...
(Date:11/25/2009)...RNewswire-USNewswire/--RemediumTechnologiesInc.,ac...erebleeding,wonfirstprizeand$10,000intheMostPromis...e2009,companyofficialsannouncetoday. ,, Selecte...,steampitchedtheirinventionattheGSCSecuritySummitc...medium( www.remediumtechnologies.com )isdeveloping...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 1Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 2Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 3Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A S on LNA Drug Platform 13659 4Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE 28R 29 13656 1Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE 28R 29 13656 2Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 1Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 2Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 3Santaris Pharma A S Forms Strategic Alliance With Shire plc to Develop RNA Based Medicines for the Treatment of Rare Genetic Disorders 13655 4
...SAN MATEO, Calif., Jan. 8 Corthera Inc. today ann...hase II clinical trial of,Relaxin, a naturally occ...,acute heart failure and other acute care illnesse...afety of Relaxin in,patients with acute heart fail...from more than 50 investigational centers worldwid...
...DEERFIELD, Ill., Jan. 7 Baxter International,Inc....ed pre-clinical,programs to develop recombinant Fa...l develop both an unmodified recombinant Factor IX...and a chemically modified, long-acting,version of ...leeding in,hemophilia B patients. Hemophilia B is ...
Other Medicine Technology:Corthera Initiates Phase II Clinical Trial of Relaxin in Acute Heart Failure 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3
(Date:11/26/2009)... Research Triangle Dental (...ral North Carolina, today announced the expansion ...d LUMINEER Dentist, Dr. Doug Macmillan. , ... Triangle Dental is pleased to announce that Dr. D... recently completed an additional advanced trainin...
(Date:11/25/2009)...,, KANSASCITY,Mo.,Nov.25/PRNewswire/--TheBartle...,slargestmedicalcliniconDec.9-10,whenKansasCityhos...edpeople. ,, "Thisfreecliniceventhasthepotentia...ysinsteadofjustoneandbeheldonweekdaysinsteadofover...tyFreeHealthClinicandpresidentoftheNationalAssocia...
(Date:11/25/2009)...,, LONGBEACH,Calif.,Nov.25/PRNewswire/--Thanksg...oundseniorsinthegreaterLongBeachareathankstoFaithI...IndependenceatHome(IAH),adivisionofSCANHealthPlan....ndredsofvolunteerstodeliverwarmThanksgivingmealsto...Bay,SouthLosAngelesandsurroundingcities. ,, "Ou...
(Date:11/25/2009)...,, BroadPoliticalEndorsements,Business,andPres...RNewswire-USNewswire/--Onceagain,theNationalBipola...amationendorsingtheir"Safe,tilStable"program,which...sureforbipolardisorder.Today,theNationalBipolarFou...lExpressPriorityMailfromtheLt.GovernorofLouisianaM...
(Date:11/25/2009)...Does stress increase blood pressure? This simple ...r many years. New Stress-related gene Modulates H...rease blood pressure? This simple question has be...Now new research has for the first time establishe...blood pressure response to stress in mice as well ...
Breaking Medicine News(10 mins):Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Kansas City Prepares for Largest Free Health Clinic 2Health News:SCAN Employees and Community Volunteers to Help Deliver One Thousand Thanksgiving Meals to Homebound Seniors 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2
... A new study led by Volker Heussler of the Bernhar..., Germany, has found that the malarial //parasite ... occupied by them. Till now it was known that...mune system. Heussler's team used a technique call...
... according to the research conducted by the stem c...from the Burnham Institute //for Medical Research ...ic stem cell research has inherent characteristics...s could be later used to replace diseased or damag...
... Research study on Rheumatic disease in women has ...id arthritis in women who have no genetic predispo...s is an autoimmune disease, which causes chronic i...une system to attack the body’s own tissues result...
... Giving up your regular late-night snack may be ha... may genetically change an area of the brain to ex...uthwestern Medical Center have discovered. B...ain. Even when the food stopped coming, the genes ...
... UCLA researchers found that altering the fatty ac...ude more omega-3 fatty acids and decrease the amou...ncer tumor growth rates and PSA levels. Publi...wering an inflammatory response known to promote p...
... Each year, about 40,000 children are born infecte...000 of these children suffer permanent disabilitie...abilities// can include hearing loss, vision loss,...ious disability as Down syndrome, fetal alcohol sy...
Other Medicine News:Health News:Human Embryonic Stem Cells Could Be Later Used In Therapeutic Cloning 2Health News:Timing of Food Consumption Activates Genes in Specific Brain Area 2Health News:Altering Fatty Acid Levels in Diet May Reduce Prostate Cancer Growth Rate 2Health News:Innovative Method for Creating a Human Cytomegalovirus Vaccine Outlined 2
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: